Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021
Mark W. Tenforde, Manish M. Patel, Manjusha Gaglani, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 4, pp. 118-124
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study
Adam S. Lauring, Mark W. Tenforde, James D. Chappell, et al.
BMJ (2022), pp. e069761-e069761
Open Access | Times Cited: 581
Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
Mayan Gilboa, Gili Regev‐Yochay, Michal Mandelboim, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2231778-e2231778
Open Access | Times Cited: 110
COVID-19: Challenges of Viral Variants
Jana L. Jacobs, Ghady Haidar, John W. Mellors
Annual Review of Medicine (2022) Vol. 74, Iss. 1, pp. 31-53
Open Access | Times Cited: 84
Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022
Jason Robert C Singson, Pam Daily Kirley, Huong Pham, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 27, pp. 878-884
Open Access | Times Cited: 82
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022
Amadea Britton, Peter J. Embí, Matthew E. Levy, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 42, pp. 1335-1342
Open Access | Times Cited: 68
The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future
Andrea Antinori, Mary T. Bausch-Jurken
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S4-S12
Open Access | Times Cited: 44
Vaccination of Adults With Cancer: ASCO Guideline
Mini Kamboj, Kari Bohlke, Deana M. Baptiste, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 14, pp. 1699-1721
Closed Access | Times Cited: 17
Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems — United States, August 2022
Greta M. Massetti, Brendan R. Jackson, John T. Brooks, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 33, pp. 1057-1064
Open Access | Times Cited: 65
Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2251833-e2251833
Open Access | Times Cited: 23
SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants
Dima Hattab, Mumen F. A. Amer, Zina M. Al‐Alami, et al.
Infection (2024) Vol. 52, Iss. 3, pp. 767-786
Open Access | Times Cited: 13
Impact of Obesity on Vaccination to SARS-CoV-2
Michaella-Jana C. Nasr, Elizabeth Geerling, Amelia K. Pinto
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 35
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
Xiao‐Feng He, Jiao Su, Yunan Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective
Jasmine R Marcelin, Audrey Pettifor, Holly Janes, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 5
Open Access | Times Cited: 33
Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational Study
Adam S. Lauring, Mark W. Tenforde, James D. Chappell, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 28
Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease
Trevor L. Schell, Keith L. Knutson, Sumona Saha, et al.
Inflammatory Bowel Diseases (2022) Vol. 28, Iss. 11, pp. 1781-1786
Open Access | Times Cited: 27
Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients
Irene Cassaniti, Marilena Gregorini, Federica Bergami, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 921-921
Open Access | Times Cited: 27
Prior SARS‐CoV‐2 infection and COVID‐19 vaccine effectiveness against outpatient illness during widespread circulation of SARS‐CoV‐2 Omicron variant, US Flu VE network
Sara Y. Tartof, Fagen Xie, Ruchi Yadav, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 5
Open Access | Times Cited: 16
COVID-19 outbreaks in nursing homes in Los Angeles County, March 2020–April 2022
Amanda van Rest, Anthony Clarke, Prabhu Gounder, et al.
Infection Control and Hospital Epidemiology (2025) Vol. 46, Iss. 2, pp. 136-142
Closed Access
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002417-e002417
Open Access | Times Cited: 24
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
Felix Kartnig, Daniel Mrak, Elisabeth Simader, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 292-300
Open Access | Times Cited: 22
Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study
Jennifer H. Ku, Lina S. Sy, Lei Qian, et al.
Vaccine (2023) Vol. 41, Iss. 24, pp. 3636-3646
Open Access | Times Cited: 13
COVID-19: From emerging variants to vaccination
Thilini H. Senevirathne, Demi Wekking, Joseph W. R. Swain, et al.
Cytokine & Growth Factor Reviews (2023) Vol. 76, pp. 127-141
Closed Access | Times Cited: 12
Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults
Tianyu Sun, Linwei Li, Katherine E. Mues, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 8, pp. 1771-1787
Open Access | Times Cited: 4
Effectiveness of two and three mRNA COVID‐19 vaccine doses against Omicron‐ and Delta‐Related outpatient illness among adults, October 2021–February 2022
Sara Kim, Jessie R. Chung, H. Keipp Talbot, et al.
Influenza and Other Respiratory Viruses (2022) Vol. 16, Iss. 6, pp. 975-985
Open Access | Times Cited: 18
Outcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19: a retrospective study
M. Lahouati, Charles Cazanave, Aur lie Labadie, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top